Jacobio completed the first patient dosing of the Aurora A inhibitor JAB-2485 in the United States

Jacobio Pharmaceuticals (1167.
HK) independently developed the world's first innovative drug Aurora (aurora kinase A) inhibitor JAB-2485 phase I/IIa clinical study completed the first dosing
of patients with advanced solid tumors in the United States.

JAB-2485 is a highly selective small molecule Aurora A inhibitor, there is currently no commercial equivalent product in the world, and JAB-2485 independently developed by Jacobio is the third Aurora A inhibitor
to be clinically tested in the United States.
The clinical trial will be completed independently by the Jacobio clinical team, marking the further enhancement
of Jacobio's global R&D capabilities.

Jab-2485 has good anti-tumor activity, preclinical data show that JAB-2485 has high selectivity at the biochemical and cellular levels, and the inhibitory activity of JAB-2485 on Aurora A is more than a thousand times higher than that of Aurora B, which has the potential to benefit
patients with tumors such as small cell lung cancer and triple-negative breast cancer.

Relevant studies have shown that Aurora A and SHP2 inhibitors have the potential to become one of the means to solve the resistance of KRAS G12C inhibitors, and are also expected to be used in combination with BET inhibitors to enhance the effect
of tumor killing 。 At the same time, Jacobio has four self-developed SHP2 inhibitors (JAB-3312, JAB-3068), Aurora A inhibitors (JAB-2485), KRAS G12C inhibitors (JAB-21822) and BET inhibitors (JAB-8263) in the clinical trial stage, and is expected to bring more treatment options
to patients through the development of internal combination drugs in the future.